250 related articles for article (PubMed ID: 37110717)
1. Synthesis and Evaluation of
Bendre S; Zhang Z; Colpo N; Zeisler J; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110717
[TBL] [Abstract][Full Text] [Related]
2. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of
Zhao L; Niu B; Fang J; Pang Y; Li S; Xie C; Sun L; Zhang X; Guo Z; Lin Q; Chen H
J Nucl Med; 2022 Jun; 63(6):862-868. PubMed ID: 34556528
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Preclinical Evaluation of Novel
Bendre S; Kuo HT; Merkens H; Zhang Z; Wong AAWL; Bénard F; Lin KS
Pharmaceuticals (Basel); 2023 May; 16(6):. PubMed ID: 37375746
[TBL] [Abstract][Full Text] [Related]
5. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
6.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Preclinical Evaluation of Three Novel
Verena A; Zhang Z; Kuo HT; Merkens H; Zeisler J; Wilson R; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770755
[TBL] [Abstract][Full Text] [Related]
8. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
9. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
[TBL] [Abstract][Full Text] [Related]
10. Novel
Verena A; Kuo HT; Merkens H; Zeisler J; Bendre S; Wong AAWL; Bénard F; Lin KS
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986548
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [
Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S
Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677
[TBL] [Abstract][Full Text] [Related]
13. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Preclinical Evaluation of Two Novel
Verena A; Merkens H; Chen CC; Chapple DE; Wang L; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398552
[TBL] [Abstract][Full Text] [Related]
15. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
[TBL] [Abstract][Full Text] [Related]
16. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [
Backhaus P; Gierse F; Burg MC; Büther F; Asmus I; Dorten P; Cufe J; Roll W; Neri D; Cazzamalli S; Millul J; Mock J; Galbiati A; Zana A; Schäfers KP; Hermann S; Weckesser M; Tio J; Wagner S; Breyholz HJ; Schäfers M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1822-1832. PubMed ID: 34957527
[TBL] [Abstract][Full Text] [Related]
17. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
18. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
Millul J; Koepke L; Haridas GR; Sparrer KMJ; Mansi R; Fani M
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3050-3061. PubMed ID: 37261473
[TBL] [Abstract][Full Text] [Related]
20. Correlation of
Mona CE; Benz MR; Hikmat F; Grogan TR; Lueckerath K; Razmaria A; Riahi R; Slavik R; Girgis MD; Carlucci G; Kelly KA; French SW; Czernin J; Dawson DW; Calais J
J Nucl Med; 2022 Jul; 63(7):1021-1026. PubMed ID: 34740953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
